Literature DB >> 23009122

Novel NMDA receptor modulators: an update.

Rose M Santangelo1, Timothy M Acker, Sommer S Zimmerman, Brooke M Katzman, Katie L Strong, Stephen F Traynelis, Dennis C Liotta.   

Abstract

INTRODUCTION: The NMDA receptor is a ligand-gated ion channel that plays a critical role in higher level brain processes and has been implicated in a range of neurological and psychiatric conditions. Although initial studies for the use of NMDA receptor antagonists in neuroprotection were unsuccessful, more recently, NMDA receptor antagonists have shown clinical promise in other indications such as Alzheimer's disease, Parkinson's disease, pain and depression. Based on the clinical observations and more recent insights into receptor pharmacology, new modulatory approaches are beginning to emerge, with potential therapeutic benefit. AREAS COVERED: The article covers the known pharmacology and important features regarding NMDA receptors and their function. A discussion of pre-clinical and clinical relevance is included, as well. The subsequent patent literature review highlights the current state of the art targeting the receptor since the last review in 2010. EXPERT OPINION: The complex nature of the NMDA receptor structure and function is becoming better understood. As knowledge about this receptor increases, it opens up new opportunities for targeting the receptor for many therapeutic indications. New strategies and advances in older technologies will need to be further developed before clinical success can be achieved. First-in-class potentiators and subunit-selective agents form the basis for most new strategies, complemented by efforts to limit off-target liability and fine-tune on-target properties.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23009122      PMCID: PMC3677696          DOI: 10.1517/13543776.2012.728587

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN: 1354-3776            Impact factor:   6.674


  134 in total

Review 1.  Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators.

Authors:  Daniel T Monaghan; Mark W Irvine; Blaise Mathias Costa; Guangyu Fang; David E Jane
Journal:  Neurochem Int       Date:  2012-01-17       Impact factor: 3.921

2.  Nickel differentially affects NMDA receptor channels in developing cultured rat neurons.

Authors:  Paola Gavazzo; Monica Mazzolini; Mariateresa Tedesco; Carla Marchetti
Journal:  Brain Res       Date:  2006-02-21       Impact factor: 3.252

3.  Design, Synthesis, and Biological Evaluation of 3-Benzazepin-1-ols as NR2B-Selective NMDA Receptor Antagonists.

Authors:  Bastian Tewes; Bastian Frehland; Dirk Schepmann; Kai-Uwe Schmidtke; Thomas Winckler; Bernhard Wünsch
Journal:  ChemMedChem       Date:  2010-05-03       Impact factor: 3.466

4.  Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain.

Authors:  Douglas J Cook; Lucy Teves; Michael Tymianski
Journal:  Nature       Date:  2012-02-29       Impact factor: 49.962

Review 5.  Ketamine as a novel antidepressant: from synapse to behavior.

Authors:  J W Murrough
Journal:  Clin Pharmacol Ther       Date:  2011-12-28       Impact factor: 6.875

6.  Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.

Authors:  Ronan Depoortère; Gihad Dargazanli; Genevieve Estenne-Bouhtou; Annick Coste; Christophe Lanneau; Christophe Desvignes; Martine Poncelet; Michel Heaulme; Vincent Santucci; Michel Decobert; Annie Cudennec; Carolle Voltz; Denis Boulay; Jean Paul Terranova; Jeanne Stemmelin; Pierre Roger; Benoit Marabout; Mireille Sevrin; Xavier Vigé; Bruno Biton; Régis Steinberg; Dominique Françon; Richard Alonso; Patrick Avenet; Florence Oury-Donat; Ghislaine Perrault; Guy Griebel; Pascal George; Philippe Soubrié; Bernard Scatton
Journal:  Neuropsychopharmacology       Date:  2005-11       Impact factor: 7.853

7.  Structure-activity relationships for allosteric NMDA receptor inhibitors based on 2-naphthoic acid.

Authors:  Blaise Mathias Costa; Mark W Irvine; Guangyu Fang; Richard J Eaves; Maria Belen Mayo-Martin; Bodo Laube; David E Jane; Daniel T Monaghan
Journal:  Neuropharmacology       Date:  2011-12-06       Impact factor: 5.250

Review 8.  Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?

Authors:  Chrysanthy Ikonomidou; Lechoslaw Turski
Journal:  Lancet Neurol       Date:  2002-10       Impact factor: 44.182

Review 9.  Rationale for and use of NMDA receptor antagonists in Parkinson's disease.

Authors:  Penelope J Hallett; David G Standaert
Journal:  Pharmacol Ther       Date:  2004-05       Impact factor: 12.310

10.  Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors.

Authors:  Erkan Karakas; Noriko Simorowski; Hiro Furukawa
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

View more
  28 in total

Review 1.  A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease.

Authors:  Giulia Ambrosi; Silvia Cerri; Fabio Blandini
Journal:  J Neural Transm (Vienna)       Date:  2014-01-01       Impact factor: 3.575

Review 2.  Retour aux sources: defining the structural basis of glutamate receptor activation.

Authors:  G Brent Dawe; Mark R Aurousseau; Bryan A Daniels; Derek Bowie
Journal:  J Physiol       Date:  2014-10-21       Impact factor: 5.182

3.  Molecular design of proneurogenic and neuroprotective compounds-allosteric NMDA receptor modulators.

Authors:  D S Karlov; E V Radchenko; V A Palyulin; N S Zefirov
Journal:  Dokl Biochem Biophys       Date:  2017-05-17       Impact factor: 0.788

4.  Synthesis and Preliminary Evaluations of a Triazole-Cored Antagonist as a PET Imaging Probe ([18F]N2B-0518) for GluN2B Subunit in the Brain.

Authors:  Hualong Fu; Weiting Tang; Zhen Chen; Vasily V Belov; Genwei Zhang; Tuo Shao; Xiaofei Zhang; Qingzhen Yu; Jian Rong; Xiaoyun Deng; Wei Han; Scott J Myers; Pilar Giffenig; Lu Wang; Lee Josephson; Yihan Shao; April T Davenport; James B Daunais; Mikhail Papisov; Hongjie Yuan; Zijing Li; Stephen F Traynelis; Steven H Liang
Journal:  ACS Chem Neurosci       Date:  2019-02-27       Impact factor: 4.418

5.  Metallaphotoredox Difluoromethylation of Aryl Bromides.

Authors:  Vlad Bacauanu; Sébastien Cardinal; Motoshi Yamauchi; Masaru Kondo; David F Fernández; Richard Remy; David W C MacMillan
Journal:  Angew Chem Int Ed Engl       Date:  2018-08-28       Impact factor: 15.336

6.  An NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups.

Authors:  Riley Perszyk; Brooke M Katzman; Hirofumi Kusumoto; Steven A Kell; Matthew P Epplin; Yesim A Tahirovic; Rhonda L Moore; David Menaldino; Pieter Burger; Dennis C Liotta; Stephen F Traynelis
Journal:  Elife       Date:  2018-05-24       Impact factor: 8.140

Review 7.  Current and Future Issues in the Development of Spinal Agents for the Management of Pain.

Authors:  Tony L Yaksh; Casey J Fisher; Tyler M Hockman; Ashley J Wiese
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

8.  A Novel Negative Allosteric Modulator Selective for GluN2C/2D-Containing NMDA Receptors Inhibits Synaptic Transmission in Hippocampal Interneurons.

Authors:  Sharon A Swanger; Katie M Vance; Timothy M Acker; Sommer S Zimmerman; John O DiRaddo; Scott J Myers; Christoffer Bundgaard; Cara A Mosley; Samantha L Summer; David S Menaldino; Henrik S Jensen; Dennis C Liotta; Stephen F Traynelis
Journal:  ACS Chem Neurosci       Date:  2017-11-02       Impact factor: 4.418

9.  The Structure-Activity Relationship of a Tetrahydroisoquinoline Class of N-Methyl-d-Aspartate Receptor Modulators that Potentiates GluN2B-Containing N-Methyl-d-Aspartate Receptors.

Authors:  Katie L Strong; Matthew P Epplin; John Bacsa; Christopher J Butch; Pieter B Burger; David S Menaldino; Stephen F Traynelis; Dennis C Liotta
Journal:  J Med Chem       Date:  2017-06-26       Impact factor: 7.446

10.  Potential involvement of GRIN2B encoding the NMDA receptor subunit NR2B in the spectrum of Alzheimer's disease.

Authors:  Virginia Andreoli; Elvira Valeria De Marco; Francesca Trecroci; Rita Cittadella; Gemma Di Palma; Antonio Gambardella
Journal:  J Neural Transm (Vienna)       Date:  2013-12-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.